A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who halt conventional lifestyle programs.
Published data in a leading medical journal shows that while obese individuals can lose about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such medications should be aware of the risk of quick weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about 18 months.
Weighing Therapies
The analysis, which looked at dozens of trials involving thousands of patients, compared the outcomes of the injectable medications with older methods.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally see a slower creep back—approximately 100 grams monthly—once they finish.
The Reason for the Quick Regain
Experts propose the mode of action of the jabs is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations several times higher than normal might result in the body to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication results in appetite is uncontrolled, making excessive eating far more likely."
A Chronic Condition?
Health authorities advise the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, due to the significant potential of weight regain, the therapy should be considered long-term.
This opinion is reinforced by pharmaceutical companies, who state that the findings "emphasize the chronic nature of excess weight," akin to managing conditions like hypertension.
Patient Accounts
People who have discontinued the medication explain a powerful return of hunger.
"I experienced something flipping and you're instantly starving," said a patient.
This difficulty is exacerbated if individuals have not established permanent dietary or behavioural modifications during therapy.
Growing Use
Figures suggest that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent fix and long-term success relies on combined lifestyle changes.
